<DOC>
	<DOCNO>NCT02762500</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety LYC-30937-EC give orally daily subject active ulcerative colitis ( UC ) define total Mayo score ( TMS ) 4-11 inclusive , endoscopic score ≥ 2 rectal bleed score ≥ 1 screening .</brief_summary>
	<brief_title>An Efficacy Safety Study LYC-30937-EC Subjects With Active Ulcerative Colitis</brief_title>
	<detailed_description>Approximately 120 subject randomize receive either enteric-coated LYC-30937-EC 25 mg PO QD match placebo PO QD duration 8 week . Randomization stratify base previous exposure anti-TNF agent least 50 % randomized subject anti-TNF naïve . The study consist 3 phase : - screen phase : 4 week - double-blind placebo-controlled phase treatment : 8 week - post-treatment follow-up : 2 week Eligible subject randomize Week 0 ( Study Day 1 ) either LYC-30937-EC 25 mg placebo . Screening occur Study Days -28 -1 . Randomization first dose occur Week 0/Study Day 1 . Double-blind study visit occur Weeks 2 , 4 , 8 , last dose Week 8/Study Day 57 . Subjects return Week 10 post-treatment safety follow-up visit .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Clinical UC diagnosis ≥ 6 month prior screen minimum disease extent ≥ 15cm anal verge . Active UC define TMS 411 ( inclusive ) endoscopic subscore ≥ 2 rectal bleed subscore ≥ 1 screening . Females childbearing potential must negative pregnancy test screen baseline visit must agree use acceptable method birth control trial 30 day take last dose study drug . Must currently receive treatment oral aminosalicylates ( ASA ) ≥ 6 week stable dose ≥ 3 week prior screen screen endoscopy and/or prednisone ( dose 20 mg daily ) equivalent ≥ 4 week receive stable dose ≥ 2 week prior screen endoscopy able provide write informed consent compliant study procedure . History Crohn 's disease ( CD ) indeterminate colitis presence history fistula consistent CD . Presence colon polyp . Severe extensive disease investigator discretion likely require colonic surgery 8 week doubleblind portion trial ( eg , fulminant colitis , toxic megacolon , bowel perforation , evidence acute abdomen ) . History alcohol drug abuse within 1 year randomization . History cancer include solid tumor hematological malignancy ( except basal cell situ squamous cell carcinoma skin adequately treat recurrence ≥ 1 year prior screen . History currently active primary secondary immunodeficiency . History uveitis . Clinically relevant hepatic , neurologic , pulmonary , ophthalmological , gastrointestinal , endocrine , psychiatric , major systemic disease make implementation study difficult would put subject risk participate study Positive test Clostridium difficile positive stool culture enteric pathogen presence ova parasite screen . Liver function test &gt; 1.5 x upper limit normal ( ULN ) direct bilirubin &gt; 1.5 x ULN Hemoglobin &lt; 8.5 g/dl Neutrophils &lt; 1500/mm3 White blood cell ( WBC ) count &lt; 3000/mm3 Platelets &lt; 80000 mm3 International normalized ratio ( INR ) &gt; 1.5 Treatment immunosuppressant agent within 8 week screen . Previous exposure ≥ 2 approve investigational biologic agent treat UC . History UC treatment biologic agent within 12 week screen . Treatment topical rectal 5ASA steroid within 2 week screen . Treatment investigational agent within 30 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>